Stockreport

The Medicines Company Announces that the ORION-10 Study of Inclisiran in ASCVD Patients Showed Durable and Potent Lowering of LDL-C with Twice-Yearly Dosing

MEDICINES  (MDCO) 
Last medicines earnings: 10/30 07:00 am Check Earnings Report
US:NASDAQ Investor Relations: themedicinescompany.com/investors
PDF - Inclisiran achieved 58% LDL-C lowering with time-adjusted reductions of 56% sustained over 18 months of treatment in patients with atherosclerotic cardiovascular disea [Read more]